Hologic

Hologic, Inc.

Company type	Public
Industry	Medical technology
Founded	1985 (1985)
Headquarters	Marlborough , United States
Products	Medical devices for diagnostics, surgical procedures, and medical imaging
Website	www.hologic.com

Hologic, Inc. is a United States-based company specializing in medical technology, primarily dedicated to advancing women's health through its range of medical devices used in diagnostics, surgical procedures, and medical imaging.

History

In November 2013, activist investor Carl Icahn acquired a 12.5% ownership in Hologic, which led the company to implement a poison pill strategy designed to prevent a hostile acquisition attempt. Subsequently, two board seats were filled by directors supported by Icahn; however, by March 2016, these representatives stepped down, and Icahn had completely divested his holdings by May.

Hologic expanded its portfolio in 2017 by acquiring the aesthetic medicine company Cynosure for $1.65 billion. Nonetheless, toward the end of 2019, Hologic sold Cynosure to Clayton, Dubilier & Rice for $205 million, choosing to concentrate on its primary focus within women's health sectors.

Amid the COVID-19 crisis, the company secured emergency use authorizations from the FDA in March and May 2020 for SARS-CoV-2 diagnostic tests, significantly enhancing its testing capabilities. Additionally, Hologic collaborated with plasma medicine manufacturer Grifols to increase COVID-19 testing availability in Spain and was awarded a $119 million contract by the U.S. government in November 2020 aimed at ramping up test production across several states.

Early in 2021, Hologic pursued growth via acquisitions, obtaining Biotheranostics for $230 million and SOMATEX for $64 million to strengthen its breast cancer diagnostic and biopsy offerings. In April of the same year, it announced a $795 million deal to acquire molecular diagnostics company Mobidiag, which was finalized by June.

In March 2022, Hologic took on the role of title sponsor for the WTA Tour, also becoming the official health partner of the Women's Tennis Association.

Continuing its acquisition strategy, Hologic purchased British medical device firm Endomag for $310 million in April 2024, with the transaction closing by July. Further expansion occurred in 2025 with a $350 million acquisition of Gynesonics, known for developing the Sonata System used in treating uterine fibroids.